As­traZeneca joins Boehringer In­gel­heim in cap­ping out-of-pock­et in­haler costs at $35

Just as in­sulin man­u­fac­tur­ers were pres­sured in­to cap­ping month­ly out-of-pock­et costs, in­haler man­u­fac­tur­ers are feel­ing the same heat. As­traZeneca on Mon­day joined with Boehringer In­gel­heim to cap the price of its block­buster in­halers at $35 per month.

Be­gin­ning on June 1, As­traZeneca’s four in­halers, in­clud­ing Sym­bi­cort and Air­supra, will be capped, ac­cord­ing to the com­pa­ny. As­traZeneca record­ed more than $2.3 bil­lion in Sym­bi­cort sales in 2023, but gener­ic com­pe­ti­tion en­tered the US mar­ket in the third quar­ter of last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER